0 346

Cited 3 times in

Comparative study of the efficacy of limaprost and pregabalin as single agents and in combination for the treatment of lumbar spinal stenosis: a prospective, double-blind, randomized controlled non-inferiority trial.

DC FieldValueLanguage
dc.contributor.author문성환-
dc.contributor.author석경수-
dc.date.accessioned2017-02-27T07:55:07Z-
dc.date.available2017-02-27T07:55:07Z-
dc.date.issued2016-
dc.identifier.issn1529-9430-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147031-
dc.description.abstractBACKGROUND CONTEXT: Although the simultaneous management of neuronal ischemia-related pain and compression-demyelination-related neuropathic pain is considered optimal in treating lumbar spinal stenosis (LSS), the effect of combination therapy with pregabalin and limaprost has not been elucidated. PURPOSE: This study aimed to compare the effects of limaprost and pregabalin individually and in combination for the treatment of LSS. STUDY DESIGN: This is a prospective, double-blind, double-dummy, randomized controlled trial. PATIENT SAMPLE: The sample consists of patients with LSS. OUTCOME MEASURES: The baseline-adjusted Oswestry Disability Index (ODI) score, visual analog scale (VAS) scores for leg pain, the European Quality of Life-5 dimensions (EQ-5D), and initial claudication distance (ICD). METHODS: The present study (ClinicalTrials.gov, number NCT01888536) was a prospective, double-blind, double-dummy, randomized controlled trial designed to determine the efficacy of limaprost in alleviating leg pain, improving disability, and increasing walking distance in persons with degenerative LSS in three different treatment groups: limaprost alone, pregabalin alone, and combined limaprost and pregabalin through 1:1:1 allocation. The primary outcome was the baseline-adjusted ODI score at 8 weeks after treatment. The non-inferior margin of the ODI was set at δ=10 points. RESULTS: The baseline-adjusted ODI score (primary outcome) at 8 weeks after treatment in the limaprost group was not inferior to those in the pregabalin and limaprost+pregabalin groups. The overall changes of the baseline-adjusted ODI scores, VAS scores for leg pain, the EQ-5D, and ICD during the follow-up assessments over an 8-week period (secondary end point) were not different among the three groups. The baseline-adjusted ODI scores and VAS scores for leg pain decreasedsignificantly over time after treatment in all three groups. The baseline-adjusted EQ-5D score and ICD also increased significantly over time after treatment in all three groups. CONCLUSIONS: The efficacy of limaprost for lumbar spinal stenosis was not inferior compared with that of pregabalin or the combination of limaprost and pregabalin in terms of disability. Therefore, combined treatment with limaprost and pregabalin does not provide additional relief in symptoms in patients with LSS compared with monotherapy with limaprost or pregabalin.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent756~763-
dc.languageEnglish-
dc.publisherElsevier Science Inc.-
dc.relation.isPartOfSPINE JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAlprostadil/administration & dosage-
dc.subject.MESHAlprostadil/adverse effects-
dc.subject.MESHAlprostadil/analogs & derivatives*-
dc.subject.MESHAlprostadil/therapeutic use-
dc.subject.MESHAnalgesics/administration & dosage-
dc.subject.MESHAnalgesics/adverse effects-
dc.subject.MESHAnalgesics/therapeutic use*-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLumbosacral Region/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPregabalin/administration & dosage-
dc.subject.MESHPregabalin/adverse effects-
dc.subject.MESHPregabalin/therapeutic use*-
dc.subject.MESHProspective Studies-
dc.subject.MESHQuality of Life-
dc.subject.MESHSpinal Stenosis/drug therapy*-
dc.titleComparative study of the efficacy of limaprost and pregabalin as single agents and in combination for the treatment of lumbar spinal stenosis: a prospective, double-blind, randomized controlled non-inferiority trial.-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Orthopedic Surgery-
dc.contributor.googleauthorHo-Joong Kim-
dc.contributor.googleauthorJin Hyok Kim-
dc.contributor.googleauthorYe Soo Park-
dc.contributor.googleauthorKyung-Soo Suk-
dc.contributor.googleauthorJae Hyup Lee-
dc.contributor.googleauthorMoon Soo Park-
dc.contributor.googleauthorSeong-Hwan Moon-
dc.identifier.doi10.1016/j.spinee.2016.02.049-
dc.contributor.localIdA01365-
dc.contributor.localIdA01926-
dc.relation.journalcodeJ02675-
dc.identifier.eissn1878-1632-
dc.identifier.pmid27045252-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S1529943016004393-
dc.subject.keywordCombined treatment-
dc.subject.keywordEuropean Quality of Life 5 dimension (EQ-5D)-
dc.subject.keywordInitial claudication distance-
dc.subject.keywordLimaprost-
dc.subject.keywordLumbar spinal stenosis-
dc.subject.keywordNon-inferiority trial, randomized controlled trial-
dc.subject.keywordOswestry disability index-
dc.subject.keywordPregabalin-
dc.subject.keywordVisual analog scale-
dc.contributor.alternativeNameMoon, Seong Hwan-
dc.contributor.alternativeNameSuk, Kyung Soo-
dc.contributor.affiliatedAuthorMoon, Seong Hwan-
dc.contributor.affiliatedAuthorSuk, Kyung Soo-
dc.citation.volume16-
dc.citation.number6-
dc.citation.startPage756-
dc.citation.endPage763-
dc.identifier.bibliographicCitationSPINE JOURNAL, Vol.16(6) : 756-763, 2016-
dc.date.modified2017-02-24-
dc.identifier.rimsid47063-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.